BRANFORD, Conn., Nov. 1 /PRNewswire-FirstCall/ -- 454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation , today announced that President and Chief Executive Officer, Christopher K. McLeod, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The presentation will take place at 4:55 p.m. (EST) on Tuesday, November 8, 2005 at the New York Palace Hotel in New York City.
454 Life Sciences’ presentation will be webcast live and can be accessed both at http://www.454.com and through the investor relations section of CuraGen’s website at http://www.curagen.com. The presentation will be archived with a replay available for 30 days thereafter.
Rodman & Renshaw Techvest 7th Annual Healthcare Conference will be held on November 7-9, 2005 at the New York Palace Hotel in New York City. The three-day conference explores advancements in a number of therapeutic areas including oncology, cardiovascular disease, medical device technology and infectious diseases, and brings together members of the life sciences and investment communities through a series of presentations, breakout sessions, and one-on-one informational meetings.
About 454 Life Sciences Corporation
454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation , is commercializing novel instrumentation and measurement services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. 454 Life Sciences’ Genome Sequencer 20 System enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences’ technology is the PicoTiterPlate(TM), which allows a single instrument using patented light emitting sequencing chemistries to produce over 20 million nucleotide bases per five-hour run, totaling more than 100 times the capacity of instruments using the current macro-scale technology.
454 Life Sciences offers sequencing services directly to customers on a fee for service basis at their state-of-the-art Measurement Services Center. The Genome Sequencer 20 System and reagents are available exclusively from Roche Applied Sciences. For additional information on 454, please visit http://www.454.com. For additional information on the Genome Sequencer 20 System and reagents, please visit http://www.roche-applied-science.com.
454 Life Sciences Peter Dacey Vice President, Finance info@454.com (877) 890-GNOM Noonan Russo Robert Stanislaro Account Supervisor robert.stanislaro@eurorscg.com (212) 845-4268
454 Life Sciences Corporation; CuraGen Corporation
CONTACT: Peter Dacey, Vice President, Finance of 454 Life Sciences,info@454.com, 1-877-890-GNOM; or Robert Stanislaro, Account Supervisor ofNoonan Russo, robert.stanislaro@eurorscg.com, +1-212-845-4268
